Eylward Susan sold $4K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 2,150 shares of Imunon, Inc. (IMNN) at $1.78 on 2026-07-20.

Original reporting
SEC EDGAR · Eylward Susan
Published Jul 21, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the issuer’s general counsel, including share count, price, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the disclosed transaction value is small and lacks accompanying fundamental catalysts.

03

What to watch

The absence of a 10b5-1 plan could raise scrutiny, but the filing provides no context for motive or whether other insiders are selling/buying around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-21 after-hours; sale dated 2026-07-20

Background

The article is an SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

SEC Form 4 shows IMUNON general counsel sold 2,150 shares on 2026-07-20 at $1.7816, totaling $3,830.44.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other negative disclosures.

Evidence & confidence

The filing is primary-source but the transaction size is small and does not include new company fundamentals, guidance, or regulatory/operational events.

Market effects

No clear sector read-through from a small insider sale filing.

None.

None.

Counterpoint

Insider sales can be for diversification or personal liquidity needs and may not reflect negative expectations, especially for small dollar amounts.

Key entities

  • Imunon, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Eylward Susan

    General Counsel and Corp Sec who sold 2,150 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IMNNMedAI 8/10

Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.